⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130087 | 0.88 | — | — | |
| SCHEMBL8979902 | 0.86 | — | — | |
| SCHEMBL9848932 | 0.86 | PPARG (0.49) | — | |
| SCHEMBL8031337 | 0.86 | — | — | |
| SCHEMBL8979871 | 0.86 | AGTR1 (0.48) | — | |
| Milfasartan SCHEMBL489256 | 0.85 | — | — | |
| SCHEMBL8028142 | 0.85 | — | — | |
| SCHEMBL9848928 | 0.84 | — | — | |
| SCHEMBL8018483 | 0.84 | — | — | |
| SCHEMBL9848939 | 0.83 | AGTR1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389105-A4 | METHOD OF TREATMENT | MERCK & CO INC (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1389105-A1 | METHOD OF TREATMENT | Merck & Co., Inc. (US) | 2004-02-18 | — | — | EP | claimed |
| US-20030073705-A1 | Method of treatment | SHAHINFAR SHAHNAZ (US) | 2003-04-17 | — | — | US | claimed |
| WO-2002092081-A1 | METHOD OF TREATMENT | MERCK & CO., INC. (US) | 2002-11-21 | — | — | WO | claimed |
| US-6300356-B1 | ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-10-09 | — | — | US | claimed |
| US-6201002-B1 | ADMINISTERING IMIDAZOLE DERIVATIVE TO TREAT CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2001-03-13 | — | — | US | claimed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| WO-2006086653-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060160834-A1 | Combination therapy for the treatment of hypertension | MERCK & CO., INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1389105-A4 | METHOD OF TREATMENT | MERCK & CO INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040116510-A1 | Antihypertensive agent and cholesterol absorption inhibitor combination therapy | NICHTBERGER STEVEN A (US) | 2004-06-17 | — | — | US | disclosed |
| EP-1389105-A1 | METHOD OF TREATMENT | Merck & Co., Inc. (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030073705-A1 | Method of treatment | SHAHINFAR SHAHNAZ (US) | 2003-04-17 | — | — | US | disclosed |
| WO-2002092081-A1 | METHOD OF TREATMENT | MERCK & CO., INC. (US) | 2002-11-21 | — | — | WO | disclosed |